6919 Stock Overview
Caliway Biopharmaceuticals Co.Ltd develops small molecule drugs for medical aesthetic and inflammatory disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Caliway Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$603.00 |
| 52 Week High | NT$800.00 |
| 52 Week Low | NT$187.25 |
| Beta | 0 |
| 1 Month Change | 13.99% |
| 3 Month Change | 7.49% |
| 1 Year Change | 207.65% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 831.27% |
Recent News & Updates
Shareholder Returns
| 6919 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 6.5% | -0.01% | -2.1% |
| 1Y | 207.7% | -2.7% | 25.6% |
Return vs Industry: 6919 exceeded the TW Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 6919 exceeded the TW Market which returned 25.6% over the past year.
Price Volatility
| 6919 volatility | |
|---|---|
| 6919 Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6919's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6919's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Yufang Ling | www.caliway.com.tw |
Caliway Biopharmaceuticals Co Ltd develops small molecule drugs for medical aesthetic and inflammatory disease. The company was founded in 2012 and is based in New Taipei City, Taiwan.
Caliway Biopharmaceuticals Co., Ltd. Fundamentals Summary
| 6919 fundamental statistics | |
|---|---|
| Market cap | NT$92.52b |
| Earnings (TTM) | -NT$651.00m |
| Revenue (TTM) | NT$49.98m |
1,851x
P/S Ratio-142.1x
P/E RatioIs 6919 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6919 income statement (TTM) | |
|---|---|
| Revenue | NT$49.98m |
| Cost of Revenue | NT$15.31m |
| Gross Profit | NT$34.67m |
| Other Expenses | NT$685.67m |
| Earnings | -NT$651.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.24 |
| Gross Margin | 69.37% |
| Net Profit Margin | -1,302.60% |
| Debt/Equity Ratio | 0% |
How did 6919 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 00:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caliway Biopharmaceuticals Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Capital Securities Corporation |
| Jane Jiang | Yuanta Research |